Table 3 Univariate and multivariate analyses of factors affecting PFS
From: The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
| Â | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
Variable | Â | HR (95% CI) | P value | HR (95% CI) | P value |
CSRN | – | 1.000 |  | 1.000 |  |
+ | 1.848 (1.054–3.242) | 0.032 | 1.848 (1.054–3.242) | 0.032 | |
Age | <  70 | 1.000 |  |  |  |
≥ 70 | 1.812 (0.991–3.311) | 0.054 |  |  | |
Body weight (kg) | <  60 | 1.000 |  |  |  |
≥ 60 | 1.089 (0.627–1.894) | 0.761 |  |  | |
Barcelona Clinic Liver Cancer stage | B | 1.000 | Â | Â | Â |
C | 1.498 (0.864–2.597) | 0.150 |  |  | |
Up to seven | In | 1.000 | Â | Â | Â |
Out | 1.243 (0.719–2.148) | 0.436 |  |  | |
Metastatic disease | – | 1.000 |  |  |  |
+ | 1.247 (0.703–2.214) | 0.450 |  |  | |
Previous therapy: Transcatheter treatment | – | 1.000 |  |  |  |
+ | 1.412 (0.761–2.623) | 0.274 |  |  | |
Refractory to Transcatheter treatment | – | 1.000 |  |  |  |
+ | 1.389 (0.501–2.123) | 0.360 |  |  | |
α-fetoprotein (ng/mL) | <  400 | 1.000 |  |  |  |
≥ 400 | 1.100 (0.620–1.950) | 0.745 |  |  | |
Albumin | ≥ 3.2 | 1.000 |  |  |  |
|  | <  3.2 | 2.130 (0.992–4.574) | 0.052 |  |  |